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drome-6 (38%): 4 with unstable angina and 1 each with STEMI and
NSTEMI. Clinical characteristics are given in the table. SF type was severe
(complete separation of stent segments) in 2 (13%) cases; moderate (frac-
ture > 1 strut) in 6 (38%) cases and minor (single strut fracture) in 8 (50%)
cases. SF site is given in the table. In-stent restenosis (ISR) was reported in
all:median percent stenosis 75 (IQR 58, 90)%. The types of stents involved
were: bare metal- 3(17%); older generation DES- 6(33%)-5 of which were
sirolimus eluting stents; covered: 1(6%); newer generation DES: 4(22%);
Unknown 5(28%). One patient had 2 types of stent with fracture. Six (33%)
of these stentswere implantedat a previous site of ISR. SFwasmanagedby
repeat stenting in 9 (50%); PTCA-1 (6%); observation- 4 (22%); CABG- 4
(22%).Atmedian 3.5 (IQR 2.25, 4) years of followup, 9patients (56%)had at
least one cardiovascular event (CV death, hospitalization or revasculari-
zation) including recurrent ISR- 3(19%) and recurrent chest pain syn-
dromes unrelated to coronary stenosis-3 (19%). There was no signiﬁcant
relationship between the management of the SF event (PCI, CABG or
medical management) and outcome (p¼0.66).
CONCLUSIONS SF is a rare occurrence, can be associated with any stent
type, and invariably presentswith somedegree of ISR. It is associatedwith
signiﬁcant long-termmorbidity regardless of management. A diagnosis of
ISR should raise suspicion for SF especially innewer generationDESwhere
the thin struts may make angiographic visualization of SF difﬁcult.Variable N (%)Subjects (n[16)Women 7 (44%)Race (white) 16 (100%)ComorbiditiesHypertension 14 (88%)Diabetes Mellitus 3 (19%)Dyslipidemia 15 (94%)Any history of smoking 10 (63%)Chronic Kidney Disease 1 (6%)Prior CABG 8 (50%)Stent Fractures (n[18)Stent site- native vesselRCA - proximal, distal 4 (22%)-3,1Mid-LAD 6 (33%)Ramus intermedius 1 (6%)Circumﬂex - proximal, OM 4 (22%) 1,3Stent site- graftLAD- LIMA, SVG 2 (19%) 1,1Ramus intermedius 1 (6%)Native vessel at site of prior graft anastomosis 3 (17%)CATEGORIES CORONARY: Complications
KEYWORDS PCI - Percutaneous Coronary Intervention, Restenosis,
in-stent, Stent fracture
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Impact of duration of dual antiplatelet therapy on clinical outcomes 1 year
after implantation of abluminally coated drug eluting stent with
bioresorbable polymer
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BACKGROUND Duration of dual anti-platelet therapy (DAPT) after
implantation of DES remains controversial despite clear guidelines.
Our aim was to compare clinical outcomes in patients treated with
bioresorbable polymer Nobori DES, who were under DAPT for a min-
imum of 12 months with those who stopped DAPT earlier
METHODS Information was obtained from 2 large prospective, multi-
center, multinational, single-arm, observational NOBORI registries on
duration of DAPT for 11448 patients. 8124 patients were treated with
DAPT continuously for 12 months, 3324 had stopped DAPT at different
time intervals (no-DAPT): 316 patients within 1 month (DAPT<1M), 3008
patients between 1 month and 12 months (DAPT<12M). We analyzed
impact of DAPT duration on clinical outcomes at one year.
RESULTS In the DAPT cohort patients were younger, had higher fre-
quency of diabetes and presented less often with hypertension and
renal failure or previous stroke. No-DAPT patients were older, had
more often hypertension, renal failure and previous stroke. DAPT
patients had more lesions at bifurcations and were more often com-
plex (type C). Access site in DAPT cohort was more often femoral. TLFrate at 1 year in DAPT<1M subgroup was 7.4%, any death or MI was
8.0%, and Cardiac Death or MI rate was 6.4%. For DAPT<12M it was
1.6%, 1,2% or 1.0% respectively. Target vessel failure rate was lowest
at 1.9% in DAPT<12M subgroup, followed by DAPT group with 2.7%
and DAPT<1M with 8.6%. As expected, deﬁnite and probable stent
thrombosis rate was signiﬁcantly higher in DAPT<1M subgroup 1.9%,
while it was low in DAPT<12 and in DAPT subgroup (0.3%).
CONCLUSIONS The results indicate that continuation of DAPT within
the ﬁrst month of stent implantation remains crucial. After the ﬁrst
month, shorter duration of DAPT does not have negative impact on
the one year clinical outcomes and that such practice is feasible
treatment option for patients who have received new generation DES.
Whether bioresorbable polymer and abluminal coating, as applied on
Nobori DES, have some effects on these ﬁndings remain to be seen
when results of dedicated randomized study becomes available.
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BACKGROUND Recent studies have demonstrated that newly diag-
nosed diabetes mellitus and prediabetes is common among patients
with acute myocardial infarction. We examined the 5-years clinical
outcomes of known diabetes mellitus, newly diagnosed diabetes
mellitus and prediabetes among acute myocardial infarction under-
going primary percutaneous coronary intervention.
METHODS We retrospectively analyzed a total of 4,748 acute
myocardial infarction patients who successfully underwent PCI from
January 2004 to December 2009 in COREA-AMI (COnvergent REgistry
of cAtholic and chonnAm university for AMI) registry. Patients were
stratiﬁed into four groups: “known diabetes” (n¼1494[31.5%]; re-
ported on the case report form), “newly diagnosed diabetes” (n¼517
[10.9%]; no diabetes history and HbA1c6.5), “prediabetes” (n¼884
[18.6%]; no diabetes history and 5.7HbA1c6.4, “no diabetes”
(n¼1853[39.0%]). Primary outcomes were all-cause mortality and
major adverse cardiovascular and cerebrovascular event (composite of
cardiac death, non-fatal MI, stroke, target vessel revascularization).
RESULTS Newly diagnosed diabetes was associated with greater 5-
years mortality (adjusted hazard ratio (HR) 1.421, 95% CI 1.106-1.824
and p¼0.006) and greater 5- years MACCE (adjusted HR 1.291, 95% CI
1.022-1.630 and p¼0.032). Known diabetes was also associated with
greater 5-years mortality (adjusted HR 1.471, 95% CI 1.228-1.762 and
p<0.001) and greater 5-years MACCE (adjusted HR 1.449, 95% CI
1.225-1.713 and p<0.001). Prediabetes was associated with greater 5-
years MACCE (adjusted HR 1.219, 95% CI 1.002-1.484 and p¼0.048),
but 5-years mortality was similar to those of normal patients.
CONCLUSIONS In addition to known diabetes, newly diagnosed dia-
betes and prediabetes are also an independent risk factor for long-
term MACCE in patients with acute myocardial infarction.
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